Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1175 of 1467 entries
View as:

A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period

Phase: N/A Priority: Normal
NCT ID: NCT05002933 Org: User:
Start: 05/20/21 End: 02/24/23 Due: 02/24/24

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

Phase: N/A Priority: Normal
NCT ID: NCT03436498 Org: User:
Start: 05/10/18 End: 10/06/18 Due: 10/06/19

SSR240600C Treatment in Women With Overactive Bladder

Phase: N/A Priority: Normal
NCT ID: NCT00564226 Org: User:
Start: 11/30/07 End: 02/28/09 Due: 02/28/10

Rasburicase (Fasturtec) Registration Trial

Phase: N/A Priority: Normal
NCT ID: NCT00607152 Org: User:
Start: 10/31/07 End: 01/31/09 Due: 01/31/10

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT00415142 Org: User:
Start: 12/31/06 End: 02/29/08 Due: 02/28/09

Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France

Phase: N/A Priority: Normal
NCT ID: NCT05359276 Org: User:
Start: 06/10/22 End: 12/31/24 Due: 12/31/25

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

Phase: N/A Priority: Normal
NCT ID: NCT05413369 Org: User:
Start: 07/07/22 End: 10/20/23 Due: 10/20/24

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX

Phase: N/A Priority: Normal
NCT ID: NCT00319592 Org: User:
Start: 05/31/05 End: 09/30/06 Due: 09/30/07

Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00811902 Org: User:
Start: 12/31/08 End: 03/31/10 Due: 03/31/11

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00803049 Org: User:
Start: 10/31/06 End: 12/31/15 Due: 12/31/16

Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia

Phase: N/A Priority: Normal
NCT ID: NCT00630175 Org: User:
Start: 09/30/03 End: 02/29/04 Due: 02/28/05

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Phase: N/A Priority: Normal
NCT ID: NCT03600805 Org: User:
Start: 11/20/18 End: 11/24/20 Due: 11/24/21

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT04718870 Org: User:
Start: 02/19/21 End: 11/30/22 Due: 11/30/23

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Phase: N/A Priority: Normal
NCT ID: NCT03713684 Org: User:
Start: 11/09/18 End: 01/04/21 Due: 01/04/22

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Phase: N/A Priority: Normal
NCT ID: NCT04183335 Org: User:
Start: 12/12/19 End: 02/03/22 Due: 02/03/23

Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance

Phase: N/A Priority: Normal
NCT ID: NCT00445796 Org: User:
Start: 06/30/05 End: - Due: -

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients

Phase: N/A Priority: Normal
NCT ID: NCT01895335 Org: User:
Start: 06/30/13 End: 11/30/15 Due: 11/30/16

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Phase: N/A Priority: Normal
NCT ID: NCT03930732 Org: User:
Start: 04/15/19 End: 05/02/23 Due: 05/02/24

Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT00299871 Org: User:
Start: 02/28/06 End: 08/31/07 Due: 08/31/08

Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05876767 Org: User:
Start: 10/15/21 End: 12/12/23 Due: 12/12/24

XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00272051 Org: User:
Start: 07/31/02 End: 05/31/04 Due: 05/31/05

French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)

Phase: N/A Priority: Normal
NCT ID: NCT06837454 Org: User:
Start: 02/04/25 End: 04/09/27 Due: 04/09/28

Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)

Phase: N/A Priority: Normal
NCT ID: NCT01026090 Org: User:
Start: 11/30/09 End: 12/31/11 Due: 12/31/12

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase: N/A Priority: Normal
NCT ID: NCT04045795 Org: User:
Start: 08/06/19 End: 03/27/24 Due: 03/27/25

Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity

Phase: N/A Priority: Normal
NCT ID: NCT01087658 Org: User:
Start: 02/28/10 End: 03/31/13 Due: 03/31/14